MG2050 · ALXN2050-MG-201
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ALXN2050 in adults with generalized myasthenia gravis. EudraCT: 2021-001229-26.
Sponsor: ALEXION
Phase: II
Area: Neuromuscular disorders